Dr Reddy's launches generic anti-bacterial drug in US
The company's product is a therapeutic generic equivalent of Oracea capsules (40 mg) approved by the US Food and Drug Administration (USFDA).
The company's product is a therapeutic generic equivalent of Oracea capsules (40 mg) approved by the US Food and Drug Administration (USFDA).
Shares of the company on Friday ended 0.71 per cent up at Rs 6,332.85 apiece on the BSE.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.